Practical management of patients with relapsed/refractory multiple myeloma receiving talquetamab, a GPRC5DxCD3 bispecific antibody: experience in monumenTAL-1

被引：0

作者：

Catamero, Donna ^{[1
]}

Purcell, Kiah ^{[2
]}

Ray, Chloe ^{[2
]}

Giacoia, Leora ^{[2
]}

Leahey, Sheryl ^{[3
]}

Born, Patricia ^{[4
]}

Kruyswijk, Sandy ^{[5
]}

机构：

[1] Mt Sinai Hlth Syst, New York, NY USA

[2] Mt Sinai Sch Med, New York, NY USA

[3] City Hope Natl Med Ctr, Duarte, CA USA

[4] Univ Hosp Wurzburg, Wurzburg, Germany

[5] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

NSP-03

引用

页码：S314 / S315

页数：2

共 50 条

[21] Mechanisms of Resistance and Relapse with Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 MonumenTAL-1 Study
Vishwamitra, Deeksha
Skerget, Sheri
Cortes, Diana
Lau, Onsay
Davis, Cuc
Renaud, Thomas
Tolbert, Jaszianne
Hilder, Brandi W.
Masterson, Tara J.
Campagna, Michela
Heuck, Christoph
Chari, Ajai
van de Donk, Niels W. C. J.
Verona, Raluca
BLOOD, 2023, 142
[22] Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Mancia, Stefania Stefania
Farrell, Annamaria
Louw, Karen
Florendo, Erika
Aronson, Elizabeth
Purcell, Kiah
Catamero, Donna D.
Escalon, Juliet
Thomas, Joanne
Aponte, Annel
Lamb, Angela
Kirke, Diana
Lucas, Aimee
Jagannath, Sundar
Cho, Hearn Jay
Parekh, Samir
Richter, Joshua
Sanchez, Larysa
Chari, Ajai
BLOOD, 2021, 138
[23] Prophylactic Tocilizumab to Mitigate Cytokine Release Syndrome in Patients Receiving Talquetamab for Relapsed/Refractory Multiple Myeloma: Results From the Phase 1/2 MonumenTAL-1 Study
Schinke, Carolina
Vij, Ravi
Jagannath, Sundar
Sanchez, Larysa
Pianko, Matthew
Jakubowiak, Andrzej
Masterson, Tara J.
Campagna, Michela
Zhang, Guoqiang
Gray, Kathleen
Renaud, Thomas
Lau, Bonnie W.
Morgan, Gareth
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S86 - S86
[24] Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
Chari, Ajai
Touzeau, Cyrille
Schinke, Carolina
Minnema, Monique C.
Berdeja, Jesus
Oriol, Albert
Van de Donk, Niels W. C. J.
Rodriguez Otero, Paula
Askari, Elham
Mateos, Maria-Victoria
Costa, Luciano J.
Caers, Jo
Rasche, Leo
Krishnan, Amrita Y.
Vishwamitra, Deeksha
Ma, Xuewen
Qin, Xiang
Gries, Katharine S.
Campagna, Michela
Masterson, Tara
Hilder, Brandi
Tolbert, Jaszianne
Renaud, Thomas
Goldberg, Jenna D.
Heuck, Christoph
San-Miguel, Jesus
Moreau, Philippe
BLOOD, 2022, 140
[25] Analysis of Infections and Parameters of Humoral Immunity in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Talquetamab (tal) Monotherapy in MonumenTAL-1
Rodriguez-Otero, Paula
Schinke, Carolina
Chari, Ajai
Lipe, Brea
Lavi, Noa
Rasche, Leo
Vishwamitra, Deeksha
Skerget, Sheri
Verona, Raluca
Ma, Xuewen
Khedkar, Sheetal
Hilder, Brandi
Masterson, Tara
Campagna, Michela
Renaud, Thomas
Tolbert, Jaszianne
Heuck, Christoph
Smit, M. Damiette
van de Donk, Niels
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S480 - S480
[26] Cytokine Release Syndrome in Patients Receiving Alternative Step-Up Doses of Talquetamab for Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study
Morillo, Daniel
Chamorro, Carmen Martinez
Mateos Manteca, Maria-Victoria
Costa, Luciano
Minnema, Monique
Sanchez, Larysa
Hilder, Brandi
Singh, Indrajeet
Gong, Joy
Lau, Bonnie W.
Renaud, Thomas
Rodriguez-Otero, Paula
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S74 - S75
[27] Real World Outcomes with Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody: A Single Center Experience for Relapsed/ Refractory Multiple Myeloma (RRMM)
Gill, Sarvarinder Kaur
Fleming, Erika
Gebre, Helen
Bangolo, Ayrton, I
Siegel, David S.
Vesole, David H.
Biran, Noa
Parmar, Harsh
Phull, Pooja
BLOOD, 2024, 144 : 7047 - 7048
[28] Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study
Sanchez, Larysa
Schinke, Carolina
Krishnan, Amrita
Berdeja, Jesus G.
de Donk, Niels W. C. J. van
Mateos, Maria Victoria
Chari, Ajai
Parekh, Samir
Mouhieddine, Tarek H.
Jagannath, Sundar
Bahlis, Nizar J.
Touzeau, Cyrille
Oriol, Albert
San-Miguel, Jesus
Otero, Paula Rodriguez
Minnema, Monique C.
Campagna, Michela
Masterson, Tara J.
Hilder, Brandi W.
Tolbert, Jaszianne
Renaud, Thomas
Gray, Kathleen
Smit, Damiette
Heuck, Christoph
Rasche, Leo
BLOOD, 2023, 142
[29] Evaluation of Drug-Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D x CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model
Willemin, Marie-Emilie
Gong, Jue
Hilder, Brandi W.
Masterson, Tara
Tolbert, Jaszianne
Renaud, Thomas
Heuck, Christoph
Kane, Colleen
De Zwart, Loeckie
Girgis, Suzette
Ma, Xuewen
Ouellet, Daniele
TARGETED ONCOLOGY, 2024, 19 (06) : 965 - 979
[30] Talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in relapsed/refractory multiple myeloma: efficacy and safety of patient subgroups from monumenTAL-1
Krishnan, Amrita
Costa, Luciano
Schinke, Carolina
Karlin, Lionel
Morillo, Daniel
Martinez-Chamorro, Carmen
Ye, Jing Christine
Chari, Ajai
Moreau, Philippe
Caers, Jo
Jakubowiak, Andrzej
Campagna, Michela
Masterson, Tara
Hilder, Brandi
Tolbert, Jaszianne
Renaud, Thomas
Smit, M. Damiette
Heuck, Christoph
Minnema, Monique
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S45 - S46

← 1 2 3 4 5 →